The higher incidence of pneumonia in patients treated with R-VEN may be due to more advanced disease in patients with R/R CLL, treatment-related cumulative immunosuppression (longer drug-induced B-cell depletion, T cell immunodeficiency due to previous treatment), and immunosuppression due to progressive disease manifested mainly by reduced IgG and IgA levels [8]. The gene discussed is CD79A; the disease is T-cell immunodeficiency.